Other Guidelines | Page 47 | European Cystic Fibrosis Society (ECFS)

Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients

Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation

Designing the GALAXY study: Partnering with the cystic fibrosis community to optimize assessment of gastrointestinal symptoms

ACT with CF: A telehealth and in-person feasibility study to address anxiety and depressive symptoms among people with cystic fibrosis

Psychological distress in adults with and without cystic fibrosis during the COVID-19 lockdown

CFTR plays an important role in the regulation of vascular resistance and high-fructose/salt-diet induced hypertension in mice

Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation

Pilot study suggests that the gut bacteria in people with CF change with CFTR modulator therapy

Men's health in the modern era of cystic fibrosis

Changes in airway inflammation with pseudomonas eradication in early cystic fibrosis

first
previous
…
43
44
45
46
47
48
49
50
51
…
next
last